Pulmonary disease severity in men with ΔF508 cystic fibrosis and residual chloride secretion (vol 353, pg 984, 1999)

被引：0

|

作者：

Thomas, SR

机构：

来源：

LANCET | 1999年 / 353卷 / 9166期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1804 / 1804

页数：1

相关论文

共 44 条

[41] Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers (vol 30, pg 53, 2017)
Stass, Heino
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2017, 30 (06) : 451 - 451
[42] The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study (Vol 12, pg 888, 2024)
Moll, M.
Sakornsakolpat, P.
Shrine, N.
LANCET RESPIRATORY MEDICINE, 2024, 12 (11):
[43] Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial (vol 394, pg 1940, 2019)
Heijerman, H. G. M.
McKone, E. F.
Downey, D. G.
Van Braeckel, Eva
Rowe, Steven M.
Tullis, Elizabeth
Mall, Marcus A.
Welter, John J.
Ramsey, Bonnie W.
McKee, Charlotte M.
Marigowda, Gautham
Moskowitz, Samuel M.
Waltz, David
Sosnay, Patrick R.
Simard, Christopher
Ahluwalia, Neil
Xuan, Fengjuan
Zhang, Yaohua
Taylor-Cousar, Jennifer L.
McCoy, Karen S.
LANCET, 2020, 395 (10238): : 1694 - 1694
[44] Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled, phase 3 trial (vol 5 pg 557, 2017)
Ratjen, F.
Hug, C.
Marigowda, G.
LANCET RESPIRATORY MEDICINE, 2017, 5 (08): : E28 - E28

← 1 2 3 4 5 →